Sai Life Targets 15-18% Revenue CAGR And 28-30% Margin In Medium Term

Market snapshot: Sai Life Sciences has reiterated medium-term corporate guidance targeting a 15-18% revenue CAGR over a 3-5 year horizon alongside 28-30% EBITDA margins over the next 2-3 years. The CRDMO provider continues to expand infrastructure and active drug development programs across key global pharmaceutical accounts.

Data Snapshot

• Medium-term revenue growth guidance targets 15-18% CAGR over a 3-5 year period.
• EBITDA margin target maintained at 28-30% over the next 2-3 years.
• Q2FY27 revenue from operations reached ₹659 crore, up 23% YoY from ₹537 crore.
• Q2FY27 EBITDA stood at ₹187 crore, reflecting a 28% EBITDA margin.

What's Changed

• Q2FY27 revenue grew to ₹659 crore compared to ₹537 crore in Q2FY26 (derived: 22.7% YoY expansion).
• H1FY27 consolidated revenue reached ₹1,213 crore compared to ₹1,034 crore in H1FY26 (derived: 17.3% YoY growth).
• Q2FY27 EBITDA margin achieved 28%, holding at the baseline of the company's 28-30% medium-term guidance corridor.

Key Takeaways

• Guidance Alignment: Operational performance in Q2FY27 demonstrates that revenue expansion and profitability are tracking within management's medium-term targets.
• CRO & CDMO Trajectory: Stronger outsourcing demand from global innovator pharma clients continues to drive top-line scale.
• Capex Backing: Cumulative capital expenditure of ₹621 crore in H1FY27 supports ongoing R&D and commercial manufacturing expansion.

SAHI Perspective

Sai Life Sciences' multi-year targets reflect durable structural growth within the Indian CRDMO space. Delivering a 28% EBITDA margin in Q2FY27 on revenue of ₹659 crore signals strong operational execution and margin stability as new capacity ramps up.

Market Implications

High-teens top-line CAGR guidance and upper-twenties operating margins enhance earnings visibility, reinforcing premium sector valuations across pharmaceutical contract manufacturing platforms.

Trading Signals

Market Bias: Bullish

Reported Q2FY27 revenue of ₹659 crore (up 23% YoY) and an EBITDA margin of 28% directly validate management guidance of 15-18% revenue CAGR and 28-30% EBITDA margins.

Overweight: Healthcare & Pharmaceuticals, Contract Development & Manufacturing (CDMO)

Trigger Factors:

• Sustained quarterly revenue growth above 15% YoY
• EBITDA margin retention within the 28-30% target band
• Commercial execution and asset utilization of H1FY27 capex

Time Horizon: Medium-term (3-12 months)

Industry Context

Global pharmaceutical companies are increasingly consolidating supply chains with integrated CRDMO providers capable of managing discovery through commercial production, favoring Indian CDMO players with established quality compliance.

Key Risks to Watch

• Potential delays or cancellations in client clinical pipeline progressions.
• Slower capacity utilization of newly operationalized facilities.
• Regulatory audit outcomes across main manufacturing units.

Recent Developments

In Q2FY27, Sai Life Sciences reported 23% YoY revenue growth to ₹659 crore with EBITDA of ₹187 crore and invested ₹621 crore in capital expenditure in H1FY27.

Closing Insight

Sai Life Sciences provides clear medium-term financial visibility, with a 28% baseline EBITDA margin offering operational confidence for long-term investors.

High Performance Trading with SAHI.